IntelGenx has announced the results of a clinical pilot study that suggests IntelGenx has successfully developed a product that is bioequivalent to a leading branded anti-migraine therapy. The
The US House of Representatives, and the Society of Chemical Manufacturers and Affiliates (SOCMA) have urged Congress to avoid sweeping changes to the Toxic Substances Control Act (TSCA)
Purdue Pharma and Napp Pharmaceutical have filed a patent infringement petition against Sun Pharmaceuticals and its US subsidiary. The litigation was filed following a para IV certification filed
Aterovax has announced data demonstrating that its blood test for secretory phospholipase A2 (sPLA2) activity significantly improves cardiovascular risk prediction in patients with stable coronary artery disease (CAD)
Novartis has reported new interim data from ongoing clinical trials demonstrating that a single 7.5µg dose of the influenza A(H1N1) 2009 unadjuvanted vaccine, half of the currently-approved US
Abbott has announced three-year data from the first 30 patients in the first phase of the ABSORB clinical trial, demonstrating that its fully bioabsorbable drug eluting coronary stent
“At Loyola, we determined four years ago that the rapid tests for influenza detected only 50 percent of the patients who were positive,” said Paul Schreckenberger, Ph.D., director
Genentech has submitted two supplemental Biologics License Applications (sBLAs) to the FDA for Avastin (bevacizumab) for the treatment of women who have not received chemotherapy for advanced (metastatic)
Sun Pharma announced that the FDA has granted tentative approval to an Abbreviated New Drug Application (ANDA) for generic Gleevec, imatinib mesylate tablets. These imatinib mesylate tablets, therapeutically
bioMerieux has entered into an agreement with GlaxoSmithKline (GSK) to develop a predictive test to help clinicians select the most appropriate treatment for different segments of breast cancer
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.